Levesque Eric, Ait-Ammar Nawel, Dudau Daniela, Clavieras Noémie, Feray Cyrille, Foulet Françoise, Botterel Françoise
Department of Anaesthesia and Surgical Intensive Care-Liver ICU, AP-HP Henri Mondor Hospital, 51 avenue du Maréchal de Lattre de Tassigny, 94010, Créteil, France.
Ecole Nationale Vétérinaire d'Alfort (ENVA), Faculté de Médecine de Créteil, EA Dynamyc Université Paris-Est Créteil (UPEC), 8 rue du Général Sarrail, 94010, Créteil, France.
Ann Intensive Care. 2019 Feb 18;9(1):31. doi: 10.1186/s13613-019-0502-2.
Cirrhosis is not recognised as one of the main risk factors of invasive pulmonary aspergillosis (IPA), although its prevalence is increasing. The aim of our study was to identify factors for IPA in such patients with a positive Aspergillus sp. culture in respiratory samples and to evaluate its impact on outcome.
We conducted a monocentric retrospective study between January 2005 and December 2015. All cirrhotic patients hospitalised in our liver ICU with a positive Aspergillus sp. respiratory sample were included. These patients were case-matched with cirrhotic patients without positive Aspergillus respiratory sample. Finally, the patients were classified as having putative aspergillosis or colonisation according to the criteria described previously.
In total, 986 cirrhotic patients were admitted to ICU during the study period. Among these, sixty patients had a positive Aspergillus sp. respiratory sample. Chronic obstructive pulmonary disease (COPD) comorbidity and organ supports were significantly associated with Aspergillus colonisation. Seventeen patients (28%) were diagnosed as proven or putative IPA and 43 were considered as colonised by Aspergillus sp. The median delay between ICU admission and an IPA diagnosis was 2 [2-24] days. Only COPD was predictive of the presence of IPA (OR 6.44; 95% CI 1.43-28.92; p = 0.0151) in patients with a positive Aspergillus sp. culture. The probability of in-hospital mortality was 71% in the IPA group versus 19% in the colonisation group (p = 0.0001).
Patients with cirrhosis can be at risk of IPA, especially with COPD. Antifungal agents should be given as soon as possible mainly in cirrhotic patients with COPD.
尽管肝硬化的患病率在上升,但它未被视为侵袭性肺曲霉病(IPA)的主要危险因素之一。我们研究的目的是确定呼吸道样本曲霉属培养阳性的此类患者发生IPA的因素,并评估其对预后的影响。
我们在2005年1月至2015年12月期间进行了一项单中心回顾性研究。纳入所有在我们肝脏重症监护病房住院且呼吸道样本曲霉属阳性的肝硬化患者。这些患者与呼吸道样本曲霉属阴性的肝硬化患者进行病例匹配。最后,根据先前描述的标准将患者分类为疑似曲霉病或定植。
在研究期间,共有986例肝硬化患者入住重症监护病房。其中,60例患者呼吸道样本曲霉属阳性。慢性阻塞性肺疾病(COPD)合并症和器官支持与曲霉定植显著相关。17例患者(28%)被诊断为确诊或疑似IPA,43例被认为是曲霉属定植。从入住重症监护病房到IPA诊断的中位时间为2[2 - 24]天。在曲霉属培养阳性的患者中,只有COPD可预测IPA的存在(比值比6.44;95%置信区间1.43 - 28.92;p = 0.0151)。IPA组的院内死亡率为71%,而定植组为19%(p = 0.0001)。
肝硬化患者可能有发生IPA的风险,尤其是合并COPD的患者。主要应尽快对合并COPD的肝硬化患者给予抗真菌药物。